Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Leerink Swann lifted their FY2017 earnings estimates for Gilead Sciences in a report issued on Thursday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will earn $8.82 per share for the year, up from their prior forecast of $8.37. Leerink Swann currently has a “Market Perform” rating and a $85.00 price objective on the stock. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2018 earnings at $1.72 EPS and FY2019 earnings at $6.84 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 earnings per share.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Thursday. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a report on Wednesday. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $79.02 to $96.00 in a report on Tuesday. Finally, Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $85.53.

Gilead Sciences (NASDAQ:GILD) opened at $81.17 on Friday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The stock has a market cap of $106,000.00, a PE ratio of 9.23, a price-to-earnings-growth ratio of -1.77 and a beta of 1.13.

Institutional investors have recently made changes to their positions in the stock. Welch Investments LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at approximately $144,000. Hanson & Doremus Investment Management raised its position in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 1,613 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $147,000. 75.95% of the stock is owned by hedge funds and other institutional investors.

In related news, insider John F. Milligan sold 220,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares of the company’s stock, valued at $8,241,851.60. The disclosure for this sale can be found here. Insiders sold a total of 591,666 shares of company stock worth $44,466,567 over the last 90 days. Company insiders own 1.30% of the company’s stock.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.

COPYRIGHT VIOLATION WARNING: “FY2017 Earnings Estimate for Gilead Sciences, Inc. (GILD) Issued By Leerink Swann” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/fy2017-earnings-estimate-for-gilead-sciences-inc-gild-issued-by-leerink-swann/1813510.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.